![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD...
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis PR Newswire NORTH CHICAGO, Ill., July...
AbbVie Reports Second-Quarter 2024 Financial Results PR Newswire NORTH CHICAGO, Ill., July 25, 2024 Reports Second-Quarter Diluted EPS of $0.77 on a GAAP Basis, a Decrease of 32.5 Percent;...
U.S. index futures are mixed in pre-market trading on Thursday following a sharp tech sector sell-off the previous day. At 5:17 AM, Dow Jones futures (DOWI:DJI) rose 85 points, or 0.21%. S&P...
L'Agence des médicaments du Canada octroie à AbbVie sa toute première recommandation de remboursement à durée limitée pour EPKINLY (MC) Canada...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis PR Newswire NORTH CHICAGO, Ill., July 12, 2024 Submissions are supported by the Phase 3...
AbbVie Announces Appointment of Roopal Thakkar, M.D. as Executive Vice President, Research & Development and Chief Scientific Officer PR Newswire NORTH CHICAGO, Ill., July 10, 2024 NORTH...
Tesla (NASDAQ:TSLA) – The Tesla Model Y was included for the first time on a list of plug-in electric and hybrid vehicles that a local government in China can acquire as a service car. This...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.5 | 0.5 | 0.5 | 2000 | 0.5 | CS |
4 | 0.01745 | 3.61620557455 | 0.48255 | 0.50885 | 0.443 | 1752 | 0.48632204 | CS |
12 | -0.0943 | -15.8674070335 | 0.5943 | 0.6625 | 0.4427 | 4518 | 0.54157752 | CS |
26 | -0.13504 | -21.2648022172 | 0.63504 | 0.6625 | 0.428 | 5328 | 0.53480329 | CS |
52 | 0.1264 | 33.8329764454 | 0.3736 | 0.6659 | 0.2409 | 5486 | 0.50066813 | CS |
156 | -0.5502 | -52.3900209484 | 1.0502 | 1.62 | 0.1345 | 7148 | 0.73709027 | CS |
260 | -1.6404 | -76.6398803962 | 2.1404 | 3.337 | 0.1345 | 7017 | 1.52282053 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions